Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Differential Requirements for the RAD51 Paralogs in Genome Repair and Maintenance in Human Cells.

Garcin EB, Gon S, Sullivan MR, Brunette GJ, Cian A, Concordet JP, Giovannangeli C, Dirks WG, Eberth S, Bernstein KA, Prakash R, Jasin M, Modesti M.

PLoS Genet. 2019 Oct 4;15(10):e1008355. doi: 10.1371/journal.pgen.1008355. [Epub ahead of print]

2.

The LL-100 panel: 100 cell lines for blood cancer studies.

Quentmeier H, Pommerenke C, Dirks WG, Eberth S, Koeppel M, MacLeod RAF, Nagel S, Steube K, Uphoff CC, Drexler HG.

Sci Rep. 2019 Jun 3;9(1):8218. doi: 10.1038/s41598-019-44491-x.

3.

Improving Hospital Safety Culture for Falls Prevention Through Interdisciplinary Health Education.

Lopez-Jeng C, Eberth SD.

Health Promot Pract. 2019 Apr 9:1524839919840337. doi: 10.1177/1524839919840337. [Epub ahead of print]

PMID:
30966813
4.

Combined Proteomic and In Silico Target Identification Reveal a Role for 5-Lipoxygenase in Developmental Signaling Pathways.

Brand S, Roy S, Schröder P, Rathmer B, Roos J, Kapoor S, Patil S, Pommerenke C, Maier T, Janning P, Eberth S, Steinhilber D, Schade D, Schneider G, Kumar K, Ziegler S, Waldmann H.

Cell Chem Biol. 2018 Sep 20;25(9):1095-1106.e23. doi: 10.1016/j.chembiol.2018.05.016. Epub 2018 Jun 28.

5.

ATP Content and Cell Viability as Indicators for Cryostress Across the Diversity of Life.

Bajerski F, Stock J, Hanf B, Darienko T, Heine-Dobbernack E, Lorenz M, Naujox L, Keller ERJ, Schumacher HM, Friedl T, Eberth S, Mock HP, Kniemeyer O, Overmann J.

Front Physiol. 2018 Jul 17;9:921. doi: 10.3389/fphys.2018.00921. eCollection 2018.

6.

Suitability of Yin Yang 1 transcript and protein levels for biomarker studies in B cell non-Hodgkin lymphoma.

Arribas Arranz J, Winter DN, Drexler HG, Eberth S.

Biomark Res. 2018 Mar 13;6:11. doi: 10.1186/s40364-018-0126-y. eCollection 2018.

7.

Hodgkin lymphoma cell lines: to separate the wheat from the chaff.

Drexler HG, Pommerenke C, Eberth S, Nagel S.

Biol Chem. 2018 May 24;399(6):511-523. doi: 10.1515/hsz-2017-0321. Review.

PMID:
29533902
8.

Enhanced whole exome sequencing by higher DNA insert lengths.

Pommerenke C, Geffers R, Bunk B, Bhuju S, Eberth S, Drexler HG, Quentmeier H.

BMC Genomics. 2016 May 25;17:399. doi: 10.1186/s12864-016-2698-y.

9.

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.

Drexler HG, Eberth S, Nagel S, MacLeod RA.

Leuk Lymphoma. 2016 May;57(5):1015-20. doi: 10.3109/10428194.2015.1108414. Epub 2016 Jan 4. Review.

PMID:
26727417
10.

Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.

Dai H, Ehrentraut S, Nagel S, Eberth S, Pommerenke C, Dirks WG, Geffers R, Kalavalapalli S, Kaufmann M, Meyer C, Faehnrich S, Chen S, Drexler HG, MacLeod RA.

PLoS One. 2015 Nov 23;10(11):e0139663. doi: 10.1371/journal.pone.0139663. eCollection 2015.

11.

DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control.

Kretzmer H, Bernhart SH, Wang W, Haake A, Weniger MA, Bergmann AK, Betts MJ, Carrillo-de-Santa-Pau E, Doose G, Gutwein J, Richter J, Hovestadt V, Huang B, Rico D, Jühling F, Kolarova J, Lu Q, Otto C, Wagener R, Arnolds J, Burkhardt B, Claviez A, Drexler HG, Eberth S, Eils R, Flicek P, Haas S, Humme M, Karsch D, Kerstens HHD, Klapper W, Kreuz M, Lawerenz C, Lenzek D, Loeffler M, López C, MacLeod RAF, Martens JHA, Kulis M, Martín-Subero JI, Möller P, Nage I, Picelli S, Vater I, Rohde M, Rosenstiel P, Rosolowski M, Russell RB, Schilhabel M, Schlesner M, Stadler PF, Szczepanowski M, Trümper L, Stunnenberg HG, Küppers R, Ammerpohl O, Lichter P, Siebert R, Hoffmann S, Radlwimmer B.

Nat Genet. 2015 Nov;47(11):1316-1325. doi: 10.1038/ng.3413. Epub 2015 Oct 5.

12.

Malignant hematopoietic cell lines: in vitro models for the study of primary mediastinal B-cell lymphomas.

Drexler HG, Ehrentraut S, Nagel S, Eberth S, MacLeod RA.

Leuk Res. 2015 Jan;39(1):18-29. doi: 10.1016/j.leukres.2014.11.002. Epub 2014 Nov 21. Review.

PMID:
25480038
13.

The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma.

Klingenberg M, Becker J, Eberth S, Kube D, Wilting J.

BMC Cancer. 2014 May 18;14:339. doi: 10.1186/1471-2407-14-339.

14.

The NADPH oxidase inhibitor imipramine-blue in the treatment of Burkitt lymphoma.

Klingenberg M, Becker J, Eberth S, Kube D, Wilting J.

Mol Cancer Ther. 2014 Apr;13(4):833-41. doi: 10.1158/1535-7163.MCT-13-0688. Epub 2014 Jan 30.

15.

Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma.

Walther N, Ulrich A, Vockerodt M, von Bonin F, Klapper W, Meyer K, Eberth S, Pukrop T, Spang R, Trümper L, Kube D.

Am J Pathol. 2013 Apr;182(4):1092-8. doi: 10.1016/j.ajpath.2012.12.013. Epub 2013 Jan 31.

PMID:
23375451
16.

DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4).

Quentmeier H, Eberth S, Romani J, Weich HA, Zaborski M, Drexler HG.

BMC Cancer. 2012 Jan 17;12:19. doi: 10.1186/1471-2407-12-19.

17.

The Wnt pathway destabilizes adherens junctions and promotes cell migration via β-catenin and its target gene cyclin D1.

Vlad-Fiegen A, Langerak A, Eberth S, Müller O.

FEBS Open Bio. 2012 Mar 5;2:26-31. doi: 10.1016/j.fob.2012.02.004. Print 2012.

18.

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG.

J Hematol Oncol. 2011 Feb 7;4:6. doi: 10.1186/1756-8722-4-6.

19.

Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.

Eberth S, Schneider B, Rosenwald A, Hartmann EM, Romani J, Zaborski M, Siebert R, Drexler HG, Quentmeier H.

BMC Cancer. 2010 Sep 29;10:517. doi: 10.1186/1471-2407-10-517.

Supplemental Content

Loading ...
Support Center